Target- |
Mechanism- |
Active Org.- |
Originator Org.- |
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
以安慰剂为对照,评价颈泰胶囊治疗神经根型颈椎病(气滞血瘀证)有效性和安全性随机、双盲Ⅲ期临床试验
[Translation] A randomized, double-blind phase III clinical trial to evaluate the efficacy and safety of Jingtai capsule in the treatment of cervical spondylotic radiculopathy (Qi stagnation and blood stasis syndrome) with placebo as control
以安慰剂为对照,评价颈泰胶囊治疗神经根型颈椎病(气滞血瘀证)有效性和安全性的分层区组随机、双盲单模拟、多中心Ⅲ期临床试验
[Translation] A stratified block randomized, double-blind, single-dummy, multicenter phase III clinical trial to evaluate the efficacy and safety of Jingtai capsule in the treatment of cervical spondylotic radiculopathy (Qi stagnation and blood stasis syndrome) with placebo as control
以舒筋通络颗粒、安慰剂为对照,随机双盲双模拟评价颈泰胶囊治疗神经根型颈椎病的Ⅱ期临床试验
[Translation] A phase II randomized double-blind double-dummy clinical trial evaluating Jingtai capsule in the treatment of cervical spondylotic radiculopathy using Shujintongluo granules and placebo as controls
初步评价颈泰胶囊治疗神经根型颈椎病(气滞血瘀证)的临床有效性和安全性。
[Translation] To preliminarily evaluate the clinical efficacy and safety of Jingtai Capsule in the treatment of cervical spondylotic radiculopathy (Qi stagnation and blood stasis syndrome).
100 Clinical Results associated with Shaanxi Kemai Pharmaceutical Development Co., Ltd.
0 Patents (Medical) associated with Shaanxi Kemai Pharmaceutical Development Co., Ltd.
100 Deals associated with Shaanxi Kemai Pharmaceutical Development Co., Ltd.
100 Translational Medicine associated with Shaanxi Kemai Pharmaceutical Development Co., Ltd.